Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

DEXCOM INC Director's Dealing 2023

Mar 14, 2023

30198_dirs_2023-03-14_1395d45f-4d24-48aa-a70e-e3743149878c.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: DEXCOM INC (DXCM)
CIK: 0001093557
Period of Report: 2023-03-10

Reporting Person: Leach Jacob Steven (EVP Chief Technology Officer)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2023-03-10 Common Stock D 3540 $111.399 Disposed 302946 Direct
2023-03-10 Common Stock D 7986 $111.399 Disposed 294960 Direct
2023-03-10 Common Stock D 4583 $111.399 Disposed 290377 Direct

Holdings (Non-Derivative)

Security Shares Ownership
Common Stock 47296 Indirect

Footnotes

F1: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

F2: Included in this number are 64,633 unvested restricted stock units, 25,397 of which were granted on March 8, 2023 and shall vest through March 8, 2026, 17,976 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 11,700 of which were granted on December 15, 2021 and shall vest through December 15, 2024, 9,560 of which were granted on March 8, 2021 and shall vest through March 8, 2024.

F3: Shares are held by the Gregg Family Grandchildren's Trust UAD 12/30/2010, with respect to which the reporting person's spouse is a trustee.